AzTrials
AzTrials

Type1diabetesEVaDiaNCT03528226

Exercise Training and Endothelial Function in Type 1 Diabetes

A study testing Exercise Training Procedure and Normal life procedure in people with Type1diabetes, run by University Hospital, Lille at 1 site in France.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

Endothelial dysfunction and vasoreactivity disorders are early subclinical complications of type 1 diabetes (T1D). In a preventive setting, in T1D patients still free of complications, the research of non-pharmacological interventions to improve endothelial function appears fundamental. Read more about this study

Who is it for?
Ages 18 to 50 years
Conditions the study is for
Type1diabetes
What is being tested?
Exercise Training Procedure and Normal life procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
34 participants
Where
1 siteFrance
Study dates
12 Nov 2019to Nov 2028
Phase
Interventional
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 50 years
  • All sexes
  • No healthy volunteers
  • Adult

Who may be able to join

  • Covered by social security
  • With a T1Diabete, diagnosed for at least 1 year, and free from macrovascular and microvascular diabetic complications.

Who cannot join

  • type 1 diabetes diagnoses for less than 1 year
  • MODY diabetes, mitochondrial diabetes or type 2 diabetes
  • presence of macrovascular and/or microvascular diabetic complications (retinopathy, nephropathy, neuropathy ,…)
  • Obesity (Body Mass Index > 30 kg/m²
  • Smokers
  • Hypertension
Show all 9Show fewer
  • Disabling painful discomfort for trunk, upper or lower limb movements
  • Active chronic disease or in remission (excluding type 1 diabetes)
  • Head trauma in the past

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Anne Vambergue, MD,PhD contact

320444184 ext. +33

anne.vambergue@chu-lille.fr

France1 site, 1 recruiting
  • Hop Claude Huriez Chu Lille

    Lille, 59037

    0320445962

    Recruiting

Other trials in France

About this study

Official title: Impact of Exercise Training on Endothelial Function in Adults With Type 1 Diabetes

Endothelial dysfunction and vasoreactivity disorders are early subclinical complications of type 1 diabetes (T1D). In a preventive setting, in T1D patients still free of complications, the research of non-pharmacological interventions to improve endothelial function appears fundamental.

In this randomized controlled trial, the effects of exercise training on endothelial function will be evaluated in T1D adults. Secondary objectives are to evaluate the exercise training effects on the micro and macrovascular function and exercise-induced tissue vasoreactivity and their possible neurometabolic consequences.

An improvement in vascular function, particularly endothelium-dependent, as well as in neurometabolic profile, through this non-pharmacological strategy is expected

Conditions
Type1diabetes
Being tested
Exercise Training Procedure, Normal life procedure
Keywords
Type 1 diabetes, endothelial function, exercise training, physical activity
Medical subject headings
Diabetes Mellitus, Type 1, Motor Activity

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Exercise Training ProcedureBehavioural

    Exercise training: 3 sessions - 2 supervised and 1 unsupervised - per week of 30-60 min at 65% - 80% of maximum heart rate (4 months)

  • Normal life procedureBehavioural

    No supervised exercise training during the 4 month period.

Study groups in NCT03528226
Study groupRoleWhat they receive
Exercise TrainingExperimentalNot described
Receives: Behavioral: Exercise Training Procedure
ControlOtherNot described
Receives: Behavioral: Normal life procedure

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in percent flow-mediated dilation (FMD) values

    Measured: between baseline and at 4 months

Secondary outcomes (8)
  1. Change the vascular responses

    Endothelium-dependent vasodilation capacity induced by post-occlusive reactive hyperaemia (5min occlusion) at the level of microcirculation (skin capillaries and arterioles of the hand)

    -Vasoreactivity of the cutaneous capillaries of the forearm in response to acetylcholine and sodium nitroprusside (iontophoresis)

    Measured: at baseline , at 2 months , at 4 months

  2. Change the vascular responses

    Endothelium-dependent vasodilation capacity induced by post-occlusive reactive hyperaemia (5min occlusion) at the level of microcirculation (skin capillaries and arterioles of the hand)

    -Dilatatory macrocirculation (brachial artery) and microcirculatory (capillaries of the hand) to nitroglycerine (in sublingual spraying)

    Measured: at baseline , at 2 months , at 4 months

  3. Change the vascular responses

    Endothelium-dependent vasodilation capacity induced by post-occlusive reactive hyperaemia (5min occlusion) at the level of microcirculation (skin capillaries and arterioles of the hand)

    -Evolution of the blood volume at the vastus lateralis muscle and the prefrontal cortex in response to an incremental maximal exercise

    Measured: at baseline , at 2 months , at 4 months

  4. Change in percent flow-mediated dilation (FMD) values

    Measured: between baseline and at 2 months

  5. change the maximum oxygen consumption ( VO2max)

    Measured: at baseline , at 2 months , at 4 months

  6. Change Blood marker concentrations of nitric oxide (NO)

    Measured: at baseline , at 2 months , at 4 months

  7. change Blood concentration of neurotrophic factors

    Blood concentration of neurotrophic factors and blood markers of metabolic profile

    Measured: at baseline , at 2 months , at 4 months

  8. Body composition (DEXA)

    Measured: at baseline , at 2 months , at 4 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted17 May 2018
  2. Study start12 Nov 2019
  3. Primary completionNov 2028 (estimated)
  4. Study completionNov 2028 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Health services research
Allocation
Randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
34 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03528226
Sponsor's protocol ID
2016_45.1
Other IDs
2017-A02873-50
Acronym
EVaDia
Status last verified
May 2026
First submitted
3 May 2018
Last updated
14 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

A study testing Exercise Training Procedure and Normal life procedure in people with Type1diabetes, run by University Hospital, Lille at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 2 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 14 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Anne Vambergue, MD,PhD (320444184 ext. +33, anne.vambergue@chu-lille.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in percent flow-mediated dilation (FMD) values (time frame: between baseline and at 4 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 May 2026.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in